> Publications > A self-generated electricity-driven drug delivery system for precision management of myopia

Keratometer

Photorefractor

Publication

March 11, 2025 • ✎ STRIA TECH

A self-generated electricity-driven drug delivery system for precision management of myopia

Topics:

Myopia

Myopia, Refractive Development and Eye Growth

Publication

Nano Energy (Jan 01, 2024) A self-generated electricity-driven drug delivery system for precision management of myopia

Jiang, L., Zhang, L., Dai, C., Zhao, B., Yang, Y., Wu, Z., Qu, C., Zou, L., Lin, Z.-H., Miao, Y.-B., & Shi, Y

DOI: 10.1016/j.nanoen.2023.109040 >>

This study introduces a novel self-generated electricity-driven drug delivery system (EDDDS) for precise myopia treatment. By integrating nanotechnology and smart drug delivery, the EDDDS uses drug-coated nanogenerators to release therapeutic agents like atropine directly to ocular tissues. The system is activated by electric fields generated during eye closure, enabling controlled and targeted drug administration while also alleviating ciliary muscle tension through weak voltage. This dual mechanism not only slows myopia progression but also enhances overall treatment efficacy. To validate the model, the Photorefractor was employed to measure refractive errors in guinea pigs, while the Keratometer assessed corneal curvature and radius. These tools provided precise, non-invasive measurements critical for evaluating treatment outcomes. The EDDDS demonstrates significant potential as a high-precision therapeutic approach, addressing limitations of existing myopia treatments and paving the way for future clinical applications.

Myopia presents a formidable challenge, especially in children, where clinical management involves the use of atropine and 7-methylxanthine, necessitating multiple doses, strong side effects and encountering suboptimal compliance due to children's resistance. In response to these issues, our research proposes a self-generated electricity-driven drug delivery system (EDDDS) designed for precision myopia treatment. The EDDDS intelligently releases therapeutic drugs, such as atropine, at ocular tissues using drug-coated nanogenerators, aiming to effectively slow down the progression of myopia. This system combines nanotechnology and smart drug delivery mechanisms to achieve controlled and responsive drug administration. The nanogenerators embedded in the EDDDS generate electric fields that trigger drug release upon closing eyes conditions, providing targeted treatment. Simultaneously, the weak voltage can effectively relieve the ciliary muscle, offering additional benefits for myopia management. In vitro and in vivo experiments have demonstrated the efficacy and potential of the EDDDS in precisely modulating myopia progression. The proposed EDDDS holds significant promise as an advanced and high-precision therapeutic approach for myopia management. Its potential to address the limitations of current treatments makes it a promising avenue for future research and clinical applications.